Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (NCT05686070)

Currently recruiting

Olympia-1

A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untreated participants with Follicular Lymphoma. (NCT06091254)

Currently recruiting

OPTIMA

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)

Currently recruiting

ORCHID

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID). (NCT04157335)

Recently completed/closed

ORIGIN-1

ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)

Currently recruiting

PACIFICA

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL) (NCT03165734)

Currently recruiting

PC_ASP_006

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (NCT05238116)

Currently recruiting

PEPSTEP

Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)

Currently recruiting

PERSONAL

PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)

Currently recruiting

PESTO

A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN12620001011976)

Currently recruiting

PETRANHA

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) (NCT05367440)

Currently recruiting

Pfizer B7981041

A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO (NCT06163326)

No longer recruiting

Pfizer B7981080

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO (NCT06072183)

Currently recruiting

PFOX

PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)

Currently recruiting

Pilot WLM

A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)

Currently recruiting

PiVET-ED

A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)

Currently recruiting

PMR-116-101

PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)

Recently completed/closed

POC WATCH HF

A Proof Of Concept study to evaluate the sensitivity and specificity of Wearables and Algorithm Technology for Chronic Heart Disease for improved diagnosis of Heart Failure (ACTRN12623000038695)

Currently recruiting

PoCeMR

Development of Clinical Utility for Point of Care MRI (Trial Not Registered)

Currently recruiting

POIESIS

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (NCT06479135)

Currently recruiting
20 21 22 23 24